

# Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e

Chunhua Li,<sup>1</sup> Ling Lu,<sup>1</sup> Donald G. Murphy,<sup>2</sup> Francesco Negro<sup>3</sup> and Hiroaki Okamoto<sup>4</sup>

## Correspondence

Ling Lu  
llu@kumc.edu  
Francesco Negro  
Francesco.Negro@hcuge.ch  
Hiroaki Okamoto  
hokamoto@jichi.ac.jp

<sup>1</sup>Center for Viral Oncology, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA

<sup>2</sup>Institut national de santé publique du Québec, Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada

<sup>3</sup>Divisions of Gastroenterology and Hepatology and of Clinical pathology, University Hospitals, Geneva, Switzerland

<sup>4</sup>Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan

We characterized the full-length genomes of nine hepatitis C virus genotype 3 (HCV-3) isolates: QC7, QC8, QC9, QC10, QC34, QC88, NE145, NE274 and 811. To the best of our knowledge, NE274 and NE145 were the first full-length genomes for confirming the provisionally assigned subtypes 3d and 3e, respectively, whereas 811 represented the first HCV-3 isolate that had its extreme 3' UTR terminus sequenced. Based on these full-length genomes, together with 42 references representing eight assigned subtypes and an unclassified variant of HCV-3, and 10 sequences of six other genotypes, a timescaled phylogenetic tree was reconstructed after an evolutionary analysis using a coalescent Bayesian procedure. The results indicated that subtypes 3a, 3d and 3e formed a subset with a common ancestor dated to ~202.89 [95% highest posterior density (HPD): 160.11, 264.6] years ago. The analysis of all of the HCV-3 sequences as a single lineage resulted in the dating of the divergence time to ~457.81 (95% HPD: 350.62, 587.53) years ago, whereas the common ancestor of all of the seven HCV genotypes dated to ~780.86 (95% HPD: 592.15, 1021.34) years ago. As subtype 3h and the unclassified variant were relatives, and represented the oldest HCV-3 lineages with origins in Africa and the Middle East, these findings may indicate the ancestral origin of HCV-3 in Africa. We speculate that the ancestral HCV-3 strains may have been brought to South Asia from Africa by land and/or across the sea to result in its indigenous circulation in that region. The spread was estimated to have occurred in the era after Vasco da Gama had completed his expeditions by sailing along the eastern coast of Africa to India. However, before this era, Arabians had practised slave trading from Africa to the Middle East and South Asia for centuries, which may have mediated the earliest spread of HCV-3.

Received 4 March 2014

Accepted 29 April 2014

## INTRODUCTION

Hepatitis C virus (HCV) is a blood-borne pathogen that infects an estimated >185 million people worldwide, which corresponds to 2.8% of the global population (Alter, 1999).

The GenBank/EMBL/DDBJ accession numbers for the nucleotide sequences of the HCV-3 isolates are JF735126 and KJ470612–KJ470619.

One supplementary table is available with the online version of this paper.

The infection is characterized by the establishment of chronic hepatitis in 70–85% of the infected individuals, of whom >20% subsequently develop cirrhosis, liver failure and hepatocellular carcinoma, (Hoofnagle, 2002; Zoulim *et al.*, 2003). HCV is a cause of substantial morbidity and mortality, the rates of which are expected to increase over the next decades (Williams, 1999).

HCV possesses a positive-sense ssRNA genome of ~9600 nt in length and is classified into the *Hepacivirus* genus of the *Flaviviridae* family (Thiel *et al.*, 2005). Based on a recent

paper on its expanded classification, HCV has now been divided into seven genotypes and 67 subtypes, of which 10 subtypes and an unclassified novel variant have been assigned within genotype 3 (Smith *et al.*, 2014). Different genotypes exhibit different geographical distribution patterns and are associated with different treatment outcomes. In general, genotypes 1–3 are distributed worldwide, whereas genotypes 4–7 are restricted to certain regions (Simmonds *et al.*, 2005). Clinically, those infected with genotypes 2 and 3 present a higher rate of sustained virological responses to therapy with IFN- $\alpha$  and ribavirin than those infected with genotypes 1 and 4 (Feld & Hoofnagle, 2005; Manns *et al.*, 2006). With respect to complications, the isolates of genotype 3 are linked to the development of more pronounced hepatocellular steatosis (Abid *et al.*, 2005; Hourieux *et al.*, 2007; Jackel-Cram *et al.*, 2007; Negro, 2006; Rubbia-Brandt *et al.*, 2000), an accelerated fibrosis progression rate (Bochud *et al.*, 2009), an increased risk of developing hepatocellular carcinoma (Nkontchou *et al.*, 2011) and an increased all-cause mortality (van der Meer *et al.*, 2012). Although the mechanisms involved in HCV-3-associated pathogenesis are not fully understood, they may be due to the genetic variation of the virus.

With the completion of one of our recent studies, six subtypes (3a, 3b, 3g, 3h, 3i and 3k) in genotype 3 have been confirmed and their full-length genomes have been characterized (Lu *et al.*, 2013). However, due to the availability of only partial sequences, four other subtypes (3c, 3d, 3e and 3f) have not yet been sequenced completely. In the present study, we determined the full-length genomes of subtypes 3d and 3e to partially fill this information gap.

Among the subtypes in genotype 3, both 3a and 3b are distributed worldwide and are often detected in developed countries – a phenomenon that is ascribed to their propensity of being transmitted via intravenous drug use (IDU) (Bourliere *et al.*, 2002; McCaw *et al.*, 1997; Pawlowsky *et al.*, 1995; Silini *et al.*, 1995). In contrast, other subtypes have been detected mainly in South Asia and its neighbouring regions, and thus show a higher genetic complexity that indicates their possible long-term indigenous circulation and origin in the regions (Hotta *et al.*, 1994; Lole *et al.*, 2003; Lu *et al.*, 2013; Murphy *et al.*, 2007; Okamoto *et al.*, 1994; Panigrahi *et al.*, 1996; Simmonds *et al.*, 1996, 2005; Tokita *et al.*, 1996; Valliammai *et al.*, 1995). Although a limited number of subtype 3h isolates have been detected in countries that are geographically well separated, these were obtained exclusively from immigrants who originated in Africa and showed the longest genetic distances compared with all of the other assigned subtypes (Abid *et al.*, 2000; Bernier *et al.*, 1996; Colson *et al.*, 2011; Corbet *et al.*, 2003; Murphy *et al.*, 2007). In addition to some other variants originating in the Middle East, two isolates of the provisionally proposed subtype 3l were identified recently in Iran (Amini *et al.*, 2006). These are two lines of evidence that may challenge the commonly accepted belief that HCV-3 may have its origin in South Asia (Simmonds *et al.*, 2005). Instead, the ancestral origin may have been in Africa and this genotype may have been brought to areas outside of Africa via the Middle East or across the sea

to South Asia. To test this hypothesis, we determined the full-length genomes of four subtype 3a, two subtype 3b and one subtype 3h isolates to not only calculate a molecular clock for genotype 3, but also perform evolutionary analysis. Using the sequence data retrieved from the Los Alamos HCV database (<http://www.hcv.lanl.gov>), and determined in this and previous studies, a timescaled phylogenetic tree was reconstructed. Based on this tree, the ancestral origin of HCV-3 was estimated and a new hypothesis was suggested.

## RESULTS

### Genome sequence and organization

The full-length genomes of nine HCV-3 isolates were characterized: NE145, NE274, 811, QC7, QC8, QC9, QC10, QC34 and QC88, each using 16–23 overlapping fragments. Of these isolates, 811 had a genome size of 9633 nt, beginning from the 5' terminus and ending at the extreme 3' end, with the latter obtained using 3' RACE reverse transcription (RT)-PCR. Each of the other eight genomes spanned 9458–9465 nt from the 5' UTR to the poly(U) track of the 3' UTR (Table 1). These nine genomes each contained a single ORF of 9060–9069 nt. The 5' UTRs were 339–340 nt in length, whereas the 3' UTRs varied from 52 to 234 nt. The sizes of the 10 protein-coding regions were the same as those of the H77 genome with the exception of those of the E2 and NS5A regions, which were variable in length (Table 1).

Fig. 1(a) shows an alignment of the 3' UTR sequences from six isolates, which were selected to represent different genotypes of HCV. The 811 isolate shows a 3' UTR that is 234 nt in length, consisting of a type-specific region immediately following the stop codon at the end of the NS5B region, a poly(U) stretch, a C(U)<sub>n</sub>-repeat and a highly conserved 98 nt region at the extreme 3' end (Kolykhalov *et al.*, 1996; Yamada *et al.*, 1996). Using an online computer program (<http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi>), we predicted the secondary structure for this 234 nt RNA sequence, which showed five typical hairpins, as reported previously (Fig. 1b). To obtain a better understanding of the structural similarity, we pairwise compared the 811 sequence in this region against that of the five other isolates, i.e. WS-#16, HCVgenotype4a-KM, JFH1, Th580 and H77, and revealed *p* distances of 0.225, 0.275, 0.298, 0.326 and 0.331, respectively. This finding indicated that the 811 sequence in this region was more closely related to WS-#16, which belongs to subtype 3a (Kolykhalov *et al.*, 1996). The results also indicated that the 98 nt in the extreme 3'-terminus were highly conserved among the genotypes. Although a few substitutions were observed in the very last 46 nt, these did not appear to disturb the stability of the predicted secondary structure (Fig. 1c) (Blight & Rice, 1997).

### Genotype 3 classification

Fig. 2 depicts a maximum-likelihood (ML) tree that was reconstructed with the 45 full-length HCV genome

**Table 1.** Patient information for the nine genotype 3 isolates and the variable number of nucleotides/amino acids in certain genomic regions

ID	Subtype	Origin	Full	ORF	5' UTR	E2	NS5A	3' UTR
H77	1a	USA	9646	9036/3011	341	1089/363	1344/448	269
NE274	3d	Nepal	9458	9066/3021	339	1104/368	1359/453	53
NE145	3e	Nepal	9458	9066/3021	340	1107/369	1356/452	52
811	3h	Somalia	9633	9060/3019	339	1104/368	1353/451	234
QC07	3a	Canada	9462	9066/3021	339	1107/369	1356/452	57
QC08	3a	Canada	9458	9066/3021	339	1107/369	1356/452	53
QC09	3a	Canada	9465	9066/3021	339	1107/369	1356/452	60
QC10	3a	Canada	9464	9069/3022	339	1110/370	1356/452	56
QC34	3b	Canada	9458	9066/3021	339	1107/369	1356/452	53
QC88	3b	Canada	9463	9069/3022	339	1110/370	1356/452	55

The genotype 1 sequence H77 (GenBank accession number AF009606) is included for comparison.

sequences assembled in this study. The tree shows that the nine genomes determined in this study were all classified into genotype 3, but represented different subtypes. Based on the other sequences that were co-analysed, QC7, QC8, QC9 and QC10 can be classified into subtype 3a, QC34 and QC88 can be classified into subtype 3b, and 811 can be classified into subtype 3h. In contrast, NE145 and NE274 each led to a single branch, and both formed a distantly linked twin. In the tree, a total of eight subtypes and a novel subtype equivalent represented by the QC115 variant were classified under genotype 3. These formed two subsets and three independent subtypes. From the top of the tree, subset A contained 3a, 3d and 3e, and subset B contained 3i, 3b and 3g. Below and adjacent to these two subsets was the relatively distant subtype 3k, which used to be classified as genotype 10 because of its greater genetic differences from the members of the two subsets (Tokita *et al.*, 1996). The base of the genotype 3 clade exhibited the divergent subtype 3h and the QC115 isolate, both of which showed the largest genetic differences from all other HCV-3 members. In general, when more than one sequence was grouped to form a subtype cluster, a bootstrap support of 100% was shown. Based on this tree, pairwise *p* distances were calculated by comparing subtype 3h to the other seven assigned subtypes. The results showed distances ranging from 0.261 to 0.278; the largest was from the HCV-Tr/3b, NE145/3e and QC260/3g isolates, and the smallest was from the QC268/3i isolate. Apparently, these inter-subtype genome-wide distances were larger compared with those found among other genotypes. This finding was consistent with recently described results (Smith *et al.*, 2014).


Fig. 3 presents four ML trees reconstructed using the partial sequences in the 5' UTR, core, E1 and NS5B regions, respectively. These trees showed that NE274, NE145 and 811 each represented a distinct subtype: 3d, 3e and 3h, respectively. In the Los Alamos HCV database, two subtype 3d isolates, i.e. 14980 and NE274, were recorded. The 14980 (GenBank accession number AY766524) has a determined 5' UTR sequence, but its sampling country was unknown. As it

was more closely related to an isolate of 3a, i.e. ZS633 (Xu *et al.*, 2013), than to NE274 in the 5' UTR tree, 14980 may not represent a subtype 3d isolate. Six isolates corresponding to subtype 3e were archived. Two (15201 and 15301) showed 5' UTR sequences identical to that of QC08/3a, whereas four (NICED-B2, NICED-B3, NICED-B4 and NE145) formed a solid 3e cluster based on their core region sequences (Chowdhury *et al.*, 2003). With the exception of NE145, which was completely sequenced in this study, NICED-B2, NICED-B3 and NICED-B4 were all sampled in India, whereas 15201 and 15301 were of unknown origin. The full-length genome sequence was available for one subtype 3h isolate while partial E1 sequences were available for seven others; six of these were obtained from African immigrants (SOM1, SOM2, SOM3, QC29 and 52735 were obtained from Somalia, and QC200 was obtained from Congo) and two (25186-R and 50556-R) were detected in the UK, but the patients' information is unknown. In addition, 8332488, which was obtained from an immigrant originating in Djibouti, a country that neighbours Somalia, was also classified into subtype 3h based on its cloned NS3 sequences (Colson *et al.*, 2011). Two novel HCV-3 variants were detected recently in Iran and have been assigned provisionally as subtype 3l (Amini *et al.*, 2006). The core sequences of both of these and the partial NS5B sequence of one of these were available in the Los Alamos HCV database, and were also analysed in this study. In the tree based on the core region sequences, both isolates were led by a single internal branch parallel to that of subtype 3h, whereas in the tree based on the NS5B sequences, the single sequence was more closely related to that of the QC115 isolate and those of subtype 3h than to any other sequences. Regardless, we observed that the 5' UTR sequences poorly differentiated the subtypes within genotype 3.

### Evolutionary analysis

Based on the 14 full-length subtype 3a sequences, which exhibited sampling dates covering 22 years from 1991 to






**Fig. 2.** ML tree estimated using 45 full-length genome sequences. In addition to the nine isolates determined in this study (●), references from subtypes 1a, 1b, 2a, 2b, 3a, 3b, 3d, 3e, 3g, 3k, 3i, 3h, 4a, 4d, 5a, 6a, 6i, 7a and a novel HCV-3 variant QC115 were also included. Each branch is led by an isolate and denoted by the ID of the isolate (from this and our previous studies) or its GenBank accession number. The bootstrap supports are shown in italics. Bar, 0.1 nt substitutions per site. For descriptive purposes, the genotypes and subtypes are indicated above the related branches, and the two subsets A and B are highlighted by two shaded rectangles.

2012, an evolutionary rate of  $1.289 \times 10^{-3} \pm 1.47 \times 10^{-5}$  substitutions per site per year (mean  $\pm$  1.96 SE) was estimated (see insert in Fig. 4). By increasing the SE 14.14-fold and applying this rate in a normal distribution as the prior rate to a subsequent Markov chain Monte Carlo (MCMC) procedure under the uncorrelated log-normal clock model, we analysed the 45 full-length HCV genomes assembled in this study to yield the timescaled phylogenetic tree presented in Fig. 4. This tree showed a topology highly similar to that of the tree shown in Fig. 2, with the exception that all of the tips were aligned to the right end, and all of the nodes and branches were measured by grids corresponding to the timescale shown at the tree base. This scale indicates the year at which the different branches diverged. It was estimated that subtype 3a has a common ancestor dated to  $\sim 78.26$  [95% highest posterior density (HPD): 63.04, 97.05] years ago (point A), which is after the

era in which the ancestral 3a strains diverged from the ancestor of both subtypes 3d and 3e  $\sim 202.89$  (95% HPD: 160.11, 264.6) years ago (point B). Considering both subsets A and B as a whole, the most recent common ancestor was dated to  $\sim 253.78$  (95% HPD: 199.69, 325.51) years ago (point C), whereas the analysis of genotype 3 as a single lineage dated the divergence time to  $\sim 457.81$  (95% HPD: 350.62, 587.53) years ago (point D). The inclusion of all of the analysed 45 HCV genomes representing genotypes 1–7 as a whole in the analysis resulted in the dating of the common ancestor to  $\sim 780.86$  (95% HPD: 592.15, 1021.34) years ago (point E). It was shown that both subtypes 3d and 3e were closer relatives to subtype 3a than to any other subtypes, and that these three may have represented a single epidemiological lineage during a certain period in the past. Similarly, the past co-origin of both subsets A and B was also indicated – both appeared to have diverged from each other  $\sim 100$  years





**Fig. 4.** A timescaled phylogenetic tree estimated using the 45 sequences shown in Fig. 2. Each branch is led by an isolate and is denoted by the following format: subtype\_ID\_GenBank accession number. The branch lengths represent the evolutionary time that is measured by the grids corresponding to the timescale (years) shown at the tree base. To simplify the tree, only those posterior probability scores equal to 1 are shown in italics to the left of the related nodes; otherwise, the scores are  $<1$ . Eight time points are given after running the tMRCA function of BEAST software and these are indicated with the red circles A–G at the related internal nodes. These points measure the time and the estimated 95 % HPD, which are detailed on the circles to indicate the divergence of the related HCV-3 lineages. The two subsets A and B marked in Fig. 2 are also highlighted with two shaded rectangles. Another rectangle insert, which highlights the 14 dated subtype 3a full-length genomes that were used to estimate the molecular rate, is shown in the upper left of the tree.

single subjects, a total of 5846 individual isolates were differentiated. These were obtained from different patients and their sampling countries were known. The information on their geographical distribution is summarized in Tables 2 and S1 (available in the online Supplementary Material). Table 2 shows that subtype 3a isolates had been identified worldwide and accounted for 88.6 % of the total 5846 isolates. In contrast, the numbers of other subtypes were remarkably decreased. With the exception of subtype 3b, which was found in 18 countries/regions and accounted for 8.96 % of the total 5846 isolates, the other subtypes each accounted for no more than 1.09 % of the isolates and were limited to certain regions. The results showed that the highest diversity of the lineages of HCV-3 was found in Asia (nine of the 10 subtypes plus one recombinant)

followed by North America (six subtypes and an unclassified variant). Based on the number of isolates, however, the majority of the lineages were reported in Europe (2662/5846, 45.5 %) followed by Asia, America, Australia and then the other continents.

## DISCUSSION

In this study, the full-length genome sequences of nine genotype 3 isolates of HCV, denoted QC7, QC8, QC9, QC10, QC34, QC88, NE145, NE274 and 811, were characterized. These isolates represent subtypes 3a, 3b, 3d, 3e and 3h. In previous studies, partial sequences had been determined for these isolates, but their full-length

**Table 2.** Geographical distribution of HCV-3 subtypes

Subtype	No. of countries* in which subtype is detected	No. of isolates (n=5846)		Percentage of isolates
		Into subtypes	Not into subtypes	
3a	55 (worldwide)	4632	545	88.6
3b	18 (AU, BD, BR, CA, CN, DE, GB, HK, ID, IN, JP, KH, MM, MY, NP, PK, TH, VN)	482	42	8.96
3a/3b	1 (CN)	1		0.0171
3c	1 (NP)	1		0.0171
3d	1 (NP)	1		0.0171
3e	1 (NP)	1		0.0171
3f	2 (NP, PK)	2		0.0342
3 g	2 (CA, IN)	19	4	0.394
3h	4(CA, DK, FR, SO)	7	2	0.154
3i	2 (CA, IN)	14		0.239
3k	6 (CA, ES, ID, IN, NL, PK)	49	16	1.11
3l	1 (IR)	2		0.0342
3	6 (BR, CA, ID, IN, TH, TR)		26	0.445
Total	59	5211	635	100

\*Country codes officially assigned in ISO 3166-1: AU, Australia; BD, Bangladesh; BR, Brazil; CA, Canada; CN, China; DE, Germany; DK, Denmark; ES, Spain; FR, France; GB, Great Britain; HK, Hong Kong; ID, Indonesia; IN, India; IR, Iran; JP, Japan; KH, Cambodia; MM, Myanmar; MY, Malaysia; NL, Netherlands; NP, Nepal; PK, Pakistan; SO, Somalia; TH, Thailand; TR, Turkey; VN, Viet Nam ([http://en.wikipedia.org/wiki/ISO\\_3166-1\\_alpha-2](http://en.wikipedia.org/wiki/ISO_3166-1_alpha-2)).

genomes had not been obtained (Abid *et al.*, 2000; Murphy *et al.*, 2007; Tokita *et al.*, 1994). By applying our modified approaches (Lu *et al.*, 2005), these nine isolates were entirely sequenced in the present study not only for the confirmation of their subtype assignments within genotype 3, but also for the reconstruction of a timescaled phylogenetic tree to estimate the origin and divergence of this HCV genotype.

To the best of our knowledge, NE274 and NE145 represent the first full-length genomes of subtypes 3d and 3e, respectively. In a recent paper on the expanded HCV classification, both 3d and 3e were categorized into the provisionally assigned subtypes (Smith *et al.*, 2014). As their full-length genomes were determined in this study, these two subtypes are now confirmed, which allowed us to fill the information gap. Although 811 represents the second full-length genome of subtype 3h, it is, to the best of our knowledge, the first HCV-3 full-length genome to have its extreme 3' UTR sequence characterized. Based on this information, we were able to predict its secondary structure to show its similarity to other HCV genotypes. Together with the full-length genomes of subtypes 3g, 3h, 3i and 3k obtained in one of our recent studies (Lu *et al.*, 2013), and those of four subtype 3a and two subtype 3b isolates, which were completely sequenced in this study, an expanded panel of HCV-3 full-length genomes is provided. These genomes represent all of the assigned subtypes within HCV-3 with the exception of 3c and 3f, which remain our future goals. To date, subtype 3c has three isolates archived in the Los Alamos HCV database: NE048 from Nepal, S48 from Singapore (Greene *et al.*, 1995) and JN656627 from India.

However, our reanalysis revealed that the latter two isolates can be reclassified into subtype 3a. Consequently, NE048 represents the only subtype 3c isolate that has been identified to date. Regarding subtype 3f, two isolates have been recorded: NE125 from Nepal (Tokita *et al.*, 1994) and PK64 from Pakistan (Stuyver *et al.*, 1996). Although we attempted to sequence the NE048/3c and NE125/3f isolates in the present study, we failed to provide their full-length genomes due to the limited number of samples with low viral titres. Therefore, our future studies will rely on more surveys to find additional 3c and 3f isolates in the regions in which these subtypes are indigenous.

Our recent studies have shown a very high degree of genetic diversity among the HCV-6 isolates found in South-East Asia, which therefore suggests South-East Asia as the region of origin for this oldest HCV lineage (Wang *et al.*, 2013). However, to a lesser extent, the present study also revealed the high complexity of HCV-3 isolates in the Indian subcontinent and in countries around the Indian Ocean, where 10 of the 11 assigned HCV-3 subtypes have been detected (Table 2). Based on these data, we may conclude that the Indian subcontinent is the region of origin for HCV-3. In fact, this conclusion reflects a commonly accepted belief. Regardless, the number of HCV-3 isolates reported in the Los Alamos HCV database is highest in Europe (2662/5846=45.5%) compared with those reported in other continents. This difference is observed because almost all of the European HCV-3 isolates belong to subtype 3a, with the exception of five that can be classified into other subtypes (Castillo *et al.*, 2006; Colson *et al.*, 2011; Corbet *et al.*, 2003; Ross *et al.*, 2000; van Doorn *et al.*, 1994). In



addition, subtype 3a strains have been found to be distributed worldwide because of their long-distance transmission via the IDU network. Furthermore, molecular epidemiological studies of HCV have been more frequently performed in Europe than in other continents, which has resulted in the determination of a large number of 3a sequences.

With the exception of 3a and 3b that are distributed worldwide, only a small number of the isolates of the other subtypes in genotype 3 have been detected in geographical regions outside South and South-East Asia. These include three 3g (QC260 and QC299 in Canada, BID-G1243 in Europe), 10 3i (QC100, QC102, QC125, QC238, QC268, QC270 and QC310 in Canada, BID-G1244, BID-G1245 and 17872-R in Europe), five 3k (DQ641982-85, HE974762 and NL96 in Europe, QC105 in Canada, KC118332 in Iran), nine 3h (QC29 and QC200 in Canada, SOM1, SOM2, SOM3, 52735, 25186-R, 50556-R and 8332488 in Europe) and two 3l isolates (DQ202323 and DQ065830 in Iran) (Abid *et al.*, 2000; Amini *et al.*, 2006; Bernier *et al.*, 1996; Castillo *et al.*, 2006; Colson *et al.*, 2011; Corbet *et al.*, 2003; Murphy *et al.*, 2007; Newman *et al.*, 2013; Samimi-Rad *et al.*, 2013; van Doorn *et al.*, 1994). Of these, five 3i isolates (QC100, QC102, QC125, QC238 and QC310) have been detected among Caucasians in Canada and these five isolates shared a unique insertion of 12 nt, which may indicate a single source of infection, likely via IDU (Murphy *et al.*, 2007). With the exception of these five 3i isolates, the majority of the above-described non-3a/3b isolates were from immigrants originating in South Asia or Africa, although a few were detected in the Middle East. These findings appear to agree with the above-described and commonly accepted belief that HCV-3 may have its origin in South Asia and subsequently spread to other regions. However, the ancestral origin of HCV-3 could have been in Africa, as suggested by the timescaled phylogenetic tree reconstructed in the present study. The tree shows that subtype 3h and the branch led by the QC115 isolate represent the oldest HCV-3 lineages. As all of the 3h isolates had their origins in Africa, the tree may suggest that the ancestral origin of HCV-3 is in Africa. From Africa, the ancient HCV-3 strains may have spread to South Asia either across the sea or by land via the Middle East. In support of the latter hypothesis, the novel QC115 isolate was detected in an immigrant from the Middle East (Lu *et al.*, 2013) and isolates of the newly proposed subtype 3l, which are more genetically related to subtype 3h and the Q115 isolate than to any other genotype 3 members, have been detected in Iran (Amini *et al.*, 2006). These findings suggest that there could be additional genotype 3 lineages of HCV that have not been detected in the Middle East. Based on the timescaled tree, the period during which the spread of the ancestral HCV-3 strains from Africa to the Middle East and South Asia could have occurred was estimated. This period was dated to ~457 (95 % HPD: 351, 588) years ago, i.e. in the middle of the sixteenth century (1553, 95 % HPD: 1422, 1660). Coincidentally, this time frame corresponds to the era during which Vasco da Gama

completed his expeditions by sailing along the eastern coast of Africa to India ([http://en.wikipedia.org/wiki/Vasco\\_da\\_Gama](http://en.wikipedia.org/wiki/Vasco_da_Gama)). However, before da Gama's voyages, slave trading from Eastern Africa to the Middle East and South Asia had taken place for centuries (Gordon, 1989; <http://www.arabslavetrade.com/>). Since the seventh century, Arabian traders had brought Africans across the Indian Ocean from the coasts of the Red Sea in Eritrea and Ethiopia, from the Swahili Coast of present-day Kenya, Mozambique and Tanzania, and from elsewhere in South-East Africa to present-day Iraq, Iran, Kuwait, Turkey and other parts of the Middle East, and to Pakistan and India in South Asia. Such slave-trading activities may have mediated the spread of the earliest HCV-3 strains from Eastern Africa to South Asia and the islands of Indonesia. However, additional studies on the molecular epidemiology of HCV not only in Africa but, more importantly, in the Middle East are required to obtain more solid evidence in support of this hypothesis.

In this study, we analysed the geographical distribution patterns of HCV-3 only based on the sequences archived in the Los Alamos HCV database. Their percentages represented the frequencies in the database, but not in the population. These frequencies may not really reflect the epidemiological situation although they can be a good approximation. Therefore, these percentages should be extrapolated with caution.

Errors may exist in the evolutionary analysis. For example, in this study only a limited number of HCV-3 sequences, sampled during a very short period of time from 1991 to 2011, were used for the time calibration. Among these sequences there may exist some sampling or stochastic errors, whilst such a relatively small error may be magnified in the subsequent estimation of the past histories of HCV that have lasted for centuries or millennia. Other potential errors may involve the possible saturation of nucleotide substitution and different rates along branches or within genomic regions. All evolutionary analyses of the highly variable RNA viruses such as HCV are subjected to these errors. Theoretically, the resulting data should be adjusted; unfortunately, however, we still lack the knowledge for these adjustments.

## METHODS

**Samples.** Three serum samples, NE274, NE145 and 811, were obtained from patients with chronic liver disease. Of these, both NE274 and NE145 were sampled in Nepal (Tokita *et al.*, 1994). These were selected because partial sequences that had been determined previously in these two samples represented the provisionally assigned subtypes 3d and 3e. The 811 sample was collected from a Somalian refugee in Switzerland, in which one of the first partial 3h sequences was isolated (Abid *et al.*, 2000). To yield the dated full-length genome sequences for the reconstruction of the ancestral relationship among genotype 3 isolates, six additional samples, denoted QC7, QC8, QC9, QC10, QC34 and QC88, were also included. These were obtained from patients living in the Canadian province of Quebec (Murphy *et al.*, 2007). Among these, QC7, QC8, QC9 and QC10 were sampled

in 1991 and represented subtype 3a isolates. QC34 and QC88 were sampled in 1995 and 2002, respectively, and represented subtype 3b isolates.

**PCR amplification and sequencing.** From each 100 µl serum sample, the viral RNA was extracted using the QIAamp Viral RNA Mini kit (Qiagen) following the manufacturer's protocol. The cDNA was synthesized using the RevertAid First-Strand cDNA Synthesis kit (Fermentas Life Science) under slightly modified conditions: the RNA pellet was dissolved in a random primer solution and incubated at 95 °C for 5 min before the other reagents were added. The resulting cDNA was used as a template to amplify the target sequences through conventional nested PCR. With the exception of the above-described protocols, all of the other procedures, such as the degenerate primers, the overlapping PCR strategies, the BigDye DNA sequencing method and the full-length genome sequence assembling, were the same as those reported previously (Li *et al.*, 2012; Lu *et al.*, 2013).

**Amplification of the extreme 5' end.** The extreme 5' UTR termini of the HCV-3 isolates were highly conserved. To amplify such terminal sequences through conventional PCR, a set of 5'-end degenerate primers was designed based on the known 3a and 3k sequences (forward, 5'-ACCTGCCTCTTWCAGGCGGACACT-3'; inner reverse, 5'-TGGTGCACGGTCTACGAGACCT-3'; outer reverse, 5'-CTTTGAGGTTTAGGATTTCGTGCTC-3').

**Amplification of the 3' end.** For the QC7, QC8, QC9, QC10, QC34, QC88, NE145 and NE274 isolates, the 3' termini were extended to the poly(U) tracks using conventional PCR (Li *et al.*, 2012). However, for the 811 isolate, the extreme 3' terminus was determined based on 3' RACE RT-PCR, in which the RNA was polyadenylated using the A-Plus Poly(A) Polymerase Tailing kit (Epicenter Biotechnologies) and then extracted using Tri-pure (Lu *et al.*, 2005). After the RNA pellet was resuspended, RT was performed and the cDNA was synthesized based on the poly(T) primer CACT35, which contained the 35mer (T). The resulting cDNA was then used to amplify the poly(T) ends using the CACT35 as the downstream primer and an 811-specific primer 5'-GCTATTTACTCCTGTGCTACTCC-3' (corresponding to nt 9332–9355 in the 811 genome) as the upstream primer. The PCR was performed using FastStart *Taq* DNA Polymerase (Roche) with the following strategy: a first cycle of denaturation at 95 °C for 3 min, 35 cycles of 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, and a final cycle of extension at 72 °C for 7 min. After amplification, the products were cloned into a TA vector and 10 clones were selected for DNA sequencing (Lu *et al.*, 2008).

**Inspection of genetic variations and phylogenetic analyses.** The nine full-length HCV genomes obtained were denoted according to the nucleotide numbering in the H77 genome. To reconstruct the ancestral relationship, an additional 36 full-length HCV genome sequences were retrieved from the Los Alamos HCV database (Kuiken *et al.*, 2006). These not only represented genotype 3, but also genotypes 1, 2, 4, 5, 6 and 7. A total of 45 full-length genome sequences were thus assembled using the BioEdit program (Tippmann, 2004). These were aligned to display their genomic organization and to identify the genetic differences.

Based on the 45 full-length HCV genome sequences, ML phylogenetic trees were reconstructed using MEGA5 software (Tamura *et al.*, 2011), in which the best trees were heuristically searched under the most appropriate substitution model GTR+I+Γ<sub>6</sub> using the nearest-neighbour-interchange perturbation algorithms. To assess the statistical robustness of the phylogenetic groupings, bootstrap analyses were conducted with 500 replicates.

**Evolutionary analysis.** Based on the 45 full-length HCV genome sequences assembled, an evolutionary timescale tree was further

estimated using the MCMC algorithm implemented in the BEAST package (version 1.6.1) (Drummond & Rambaut, 2007). We recently analysed the full-length subtype 1a and 1b sequences, and identified that the relaxed log-normal clock model is better than the exponential and strict models (Yuan *et al.*, 2013). Therefore, we used this model in combination with the GTR+I+Γ substitution model and the Bayesian skyline model in this study for the estimation of the timescale tree in the MCMC analysis, but we inputted an evolutionary rate of  $1.289 \times 10^{-3} \pm 1.47 \times 10^{-5}$  substitutions per site per year as the prior rate, which was estimated directly using the 14 dated 3a sequences assembled in this study using a previously described method (Yuan *et al.*, 2013). After these parameters were set, we ran the MCMC procedure for 300 million states and obtained a tree every 30 000 states. After discarding the first 10% burn-in, the output was examined for convergence through a visual inspection of the chain length and by comparing the statistics of the effective sample size (ESS) using the Tracer program (<http://tree.bio.ed.ac.uk>). In this study, sufficient sampling was considered to have been achieved when all of the ESS numbers were  $\geq 200$ . We used the TreeAnnotator program to reconstruct a tree from the resulting set of credible trees and the final tree was denoted the MCC (maximum clade credibility) tree. As a molecular clock was incorporated, the branch lengths and the tree node heights were marked in units of years. The phylogenetic structure was then displayed using the FigTree program, and the clades, lineages and internal node heights were indicated as necessary.

To further comprehend the genetic complexity of subtypes 3e, 3d, 3h and 3l, the related partial sequences available in the Los Alamos HCV database were retrieved to represent these four subtypes and analysed phylogenetically. Four datasets, denoted 5' UTR, core, E1 and NS5B, were therefore assembled.

To exclude the recent viral recombination events (Lee *et al.*, 2010; Legrand-Abravanel *et al.*, 2007), RDP3 software (Martin *et al.*, 2010) was run using the modified settings that we described previously (Lu *et al.*, 2007). This analysis was only performed for the full-length genome sequences.

**Geographical distribution of genotype 3 sequences.** A total of 7840 HCV isolates from the Los Alamos HCV database accessed on December, 2011 were classified as genotype 3. Of these, 5846 had known sampling countries and represented individual isolates. Based on these 5846 isolates, the correlation between subtypes and sampling countries was investigated.

## ACKNOWLEDGEMENTS

The study described was supported by a grant from the National Institute of Allergy and Infectious Diseases (5 R01 AI080734-03A).

## REFERENCES

- Abid, K., Quadri, R., Veuthey, A. L., Hadengue, A. & Negro, F. (2000). A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3. *J Gen Virol* **81**, 1485–1493.
- Abid, K., Paziienza, V., de Gottardi, A., Rubbia-Brandt, L., Conne, B., Pugnale, P., Rossi, C., Mangia, A. & Negro, F. (2005). An *in vitro* model of hepatitis C virus genotype 3a-associated triglycerides accumulation. *J Hepatol* **42**, 744–751.
- Alter, M. J. (1999). Hepatitis C virus infection in the United States. *J Hepatol* **31** (Suppl. 1), 88–91.
- Amini, S., Ahmadi Pour, M. H. & Azadmanesh, K. (2006). The phylogenetic analysis of hepatitis C virus isolates obtained from two

- Iranian carriers revealed evidence for a new subtype of HCV genotype 3. *Virus Genes* **33**, 271–278.
- Bernier, L., Willems, B., Delage, G. & Murphy, D. G. (1996).** Identification of numerous hepatitis C virus genotypes in Montreal, Canada. *J Clin Microbiol* **34**, 2815–2818.
- Blight, K. J. & Rice, C. M. (1997).** Secondary structure determination of the conserved 98-base sequence at the 3' terminus of hepatitis C virus genome RNA. *J Virol* **71**, 7345–7352.
- Bochud, P. Y., Cai, T., Overbeck, K., Bochud, M., Dufour, J. F., Müllhaupt, B., Borovicka, J., Heim, M., Moradpour, D. & other authors (2009).** Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* **51**, 655–666.
- Bourlière, M., Barberin, J. M., Rotily, M., Guagliardo, V., Portal, I., Lecomte, L., Benali, S., Boustière, C., Perrier, H. & other authors (2002).** Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. *J Viral Hepat* **9**, 62–70.
- Castillo, I., Rodríguez-Iñigo, E., López-Alcorocho, J. M., Pardo, M., Bartolomé, J. & Carreño, V. (2006).** Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. *Clin Infect Dis* **43**, 1277–1283.
- Chowdhury, A., Santra, A., Chaudhuri, S., Dhali, G. K., Chaudhuri, S., Maity, S. G., Naik, T. N., Bhattacharya, S. K. & Mazumder, D. N. (2003).** Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. *Hepatology* **37**, 802–809.
- Colson, P., Gayet, S. & Gerolami, R. (2011).** NS3 protease of genotype 3 subtype h HCV identified in southeastern France. *Antivir Ther* **16**, 615–619.
- Corbet, S., Bukh, J., Heinsen, A. & Fomsgaard, A. (2003).** Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. *J Clin Microbiol* **41**, 1091–1100.
- Drummond, A. J. & Rambaut, A. (2007).** BEAST: Bayesian evolutionary analysis by sampling trees. *BMC Evol Biol* **7**, 214.
- Feld, J. J. & Hoofnagle, J. H. (2005).** Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* **436**, 967–972.
- Gordon, M. (1989).** *Slavery in the Arab World*. New York: New Amsterdam Press.
- Greene, W. K., Cheong, M. K., Ng, V. & Yap, K. W. (1995).** Prevalence of hepatitis C virus sequence variants in South-East Asia. *J Gen Virol* **76**, 211–215.
- Hoofnagle, J. H. (2002).** Course and outcome of hepatitis C. *Hepatology* **36** (Suppl 1), S21–S29.
- Hotta, H., Handajani, R., Lusida, M. I., Soemarto, W., Doi, H., Miyajima, H. & Homma, M. (1994).** Subtype analysis of hepatitis C virus in Indonesia on the basis of NS5b region sequences. *J Clin Microbiol* **32**, 3049–3051.
- Hourioux, C., Patient, R., Morin, A., Blanchard, E., Moreau, A., Trassard, S., Giraudeau, B. & Roingeard, P. (2007).** The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an *in vitro* cellular model. *Gut* **56**, 1302–1308.
- Jackel-Cram, C., Babiuk, L. A. & Liu, Q. (2007).** Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. *J Hepatol* **46**, 999–1008.
- Kolykhalov, A. A., Feinstone, S. M. & Rice, C. M. (1996).** Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *J Virol* **70**, 3363–3371.
- Kuiken, C., Combet, C., Bukh, J., Shin-I, T., Deleage, G., Mizokami, M., Richardson, R., Sablon, E., Yusim, K. & other authors (2006).** A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. *Hepatology* **44**, 1355–1361.
- Lee, Y. M., Lin, H. J., Chen, Y. J., Lee, C. M., Wang, S. F., Chang, K. Y., Chen, T. L., Liu, H. F. & Chen, Y. M. (2010).** Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: full-length sequences of two new subtype 6w strains and a recombinant form\_2b6w. *J Med Virol* **82**, 57–68.
- Legrand-Abravanel, F., Claudinon, J., Nicot, F., Dubois, M., Chapuy-Regaud, S., Sandres-Saune, K., Pasquier, C. & Izopet, J. (2007).** New natural intergenotypic (2/5) recombinant of hepatitis C virus. *J Virol* **81**, 4357–4362.
- Li, C., Cao, H., Lu, L. & Murphy, D. (2012).** Full-length sequences of 11 hepatitis C virus genotype 2 isolates representing five subtypes and six unclassified lineages with unique geographical distributions and genetic variation patterns. *J Gen Virol* **93**, 1173–1184.
- Lole, K. S., Jha, J. A., Shrotri, S. P., Tandon, B. N., Prasad, V. G. & Arankalle, V. A. (2003).** Comparison of hepatitis C virus genotyping by 5' noncoding region- and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India. *J Clin Microbiol* **41**, 5240–5244.
- Lu, L., Nakano, T., He, Y., Fu, Y., Hagedorn, C. H. & Robertson, B. H. (2005).** Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. *J Med Virol* **75**, 538–549.
- Lu, L., Li, C., Fu, Y., Gao, F., Pybus, O. G., Abe, K., Okamoto, H., Hagedorn, C. H. & Murphy, D. (2007).** Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6. *J Gen Virol* **88**, 1519–1525.
- Lu, L., Tatsunori, N., Li, C., Waheed, S., Gao, F. & Robertson, B. H. (2008).** HCV selection and HVRI evolution in a chimpanzee chronically infected with HCV-1 over 12 years. *Hepatol Res* **38**, 704–716.
- Lu, L., Li, C., Yuan, J., Lu, T., Okamoto, H. & Murphy, D. G. (2013).** Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant. *J Gen Virol* **94**, 543–548.
- Manns, M. P., Wedemeyer, H. & Cornberg, M. (2006).** Treating viral hepatitis C: efficacy, side effects, and complications. *Gut* **55**, 1350–1359.
- Martin, D. P., Lemey, P., Lott, M., Moulton, V., Posada, D. & Lefevre, P. (2010).** RDP3: a flexible and fast computer program for analyzing recombination. *Bioinformatics* **26**, 2462–2463.
- McCaw, R., Moaven, L., Locarnini, S. A. & Bowden, D. S. (1997).** Hepatitis C virus genotypes in Australia. *J Viral Hepat* **4**, 351–357.
- Murphy, D. G., Willems, B., Deschênes, M., Hilzenrat, N., Mousseau, R. & Sabbah, S. (2007).** Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. *J Clin Microbiol* **45**, 1102–1112.
- Negro, F. (2006).** Mechanisms and significance of liver steatosis in hepatitis C virus infection. *World J Gastroenterol* **12**, 6756–6765.
- Newman, R. M., Kuntzen, T., Weiner, B., Berical, A., Charlebois, P., Kuiken, C., Murphy, D. G., Simmonds, P., Bennett, P. & other authors (2013).** Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. *J Infect Dis* **208**, 17–31.
- Nkontchou, G., Zioli, M., Aout, M., Lhabadie, M., Baazia, Y., Mahmoudi, A., Roulot, D., Ganne-Carrie, N., Grando-Lemaire, V. & other authors (2011).** HCV genotype 3 is associated with a higher

hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. *J Viral Hepat* **18**, e516–e522.

**Okamoto, H., Kojima, M., Sakamoto, M., Iizuka, H., Hadiwandowo, S., Suwignyo, S., Miyakawa, Y. & Mayumi, M. (1994).** The entire nucleotide sequence and classification of a hepatitis C virus isolate of a novel genotype from an Indonesian patient with chronic liver disease. *J Gen Virol* **75**, 629–635.

**Panigrahi, A. K., Roca, J., Acharya, S. K., Jameel, S. & Panda, S. K. (1996).** Genotype determination of hepatitis C virus from northern India: identification of a new subtype. *J Med Virol* **48**, 191–198.

**Pawlotsky, J. M., Tsakiris, L., Roudot-Thoraval, F., Pellet, C., Stuyver, L., Duval, J. & Dhumeaux, D. (1995).** Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. *J Infect Dis* **171**, 1607–1610.

**Ross, R. S., Viazov, S. O., Holtzer, C. D., Beyou, A., Monnet, A., Mazure, C. & Roggendorf, M. (2000).** Genotyping of hepatitis C virus isolates using CLIP sequencing. *J Clin Microbiol* **38**, 3581–3584.

**Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P. J., Mentha, G., Spahr, L., Zarski, J. P., Borisch, B. & other authors (2000).** Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* **33**, 106–115.

**Samimi-Rad, K., Asgari, F., Nasiritoosi, M., Esteghamati, A., Azarkeyvan, A., Eslami, S. M., Zamani, F., Magnius, L., Alavian, S. M. & Norder, H. (2013).** Patient-to-patient transmission of hepatitis C at Iranian thalassemia centers shown by genetic characterization of viral strains. *Hepat Mon* **13**, e7699.

**Silini, E., Bono, F., Cividini, A., Cerino, A., Maccabruni, A., Tinelli, C., Bruno, S., Bellobuono, A. & Mondelli, M. (1995).** Molecular epidemiology of hepatitis C virus infection among intravenous drug users. *J Hepatol* **22**, 691–695.

**Simmonds, P., Mellor, J., Sakuldamrongpanich, T., Nuchaprayoon, C., Tanprasert, S., Holmes, E. C. & Smith, D. B. (1996).** Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. *J Gen Virol* **77**, 3013–3024.

**Simmonds, P., Bukh, J., Combet, C., Deléage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C. & other authors (2005).** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* **42**, 962–973.

**Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T. & Simmonds, P. (2014).** Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* **59**, 318–327.

**Stuyver, L., Wyseur, A., van Arnhem, W., Hernandez, F. & Maertens, G. (1996).** Second-generation line probe assay for hepatitis C virus genotyping. *J Clin Microbiol* **34**, 2259–2266.

**Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M. & Kumar, S. (2011).** MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* **28**, 2731–2739.

**Thiel, H. J., Collett, M. S., Gould, E. A., Heinz, F. X., Houghton, M., Meyers, G., Purcell, R. H. & Rice, C. M. (2005).** Flaviviridae. In *Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses*, pp. 981–998. Edited by C. M. Fauquet, M. Mayo, J. Maniloff, U. Desselberger & L. A. Ball. San Diego, CA: Academic Press.

**Tippmann, H. F. (2004).** Analysis for free: comparing programs for sequence analysis. *Brief Bioinform* **5**, 82–87.

**Tokita, H., Shrestha, S. M., Okamoto, H., Sakamoto, M., Horikita, M., Iizuka, H., Shrestha, S., Miyakawa, Y. & Mayumi, M. (1994).** Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. *J Gen Virol* **75**, 931–936.

**Tokita, H., Okamoto, H., Iizuka, H., Kishimoto, J., Tsuda, F., Lesmana, L. A., Miyakawa, Y. & Mayumi, M. (1996).** Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. *J Gen Virol* **77**, 293–301.

**Valliammai, T., Thyagarajan, S. P., Zuckerman, A. J. & Harrison, T. J. (1995).** Diversity of genotypes of hepatitis C virus in southern India. *J Gen Virol* **76**, 711–716.

**van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P. & other authors (2012).** Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* **308**, 2584–2593.

**van Doorn, L. J., Kleter, B., Stuyver, L., Maertens, G., Brouwer, H., Schalm, S., Heijntink, R. & Quint, W. (1994).** Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles. *J Hepatol* **21**, 122–129.

**Wang, H., Yuan, Z., Barnes, E., Yuan, M., Li, C., Fu, Y., Xia, X., Li, G., Newton, P. N. & other authors (2013).** Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. *J Gen Virol* **94**, 76–80.

**Williams, I. (1999).** Epidemiology of hepatitis C in the United States. *Am J Med* **107** (Suppl 2), 2–9.

**Xu, R., Tong, W., Gu, L., Li, C., Fu, Y. & Lu, L. (2013).** A panel of full-length HCV genome sequences characterized in China representing 11 subtypes and two novel variants. *Infect Genet Evol* **20**, 225–229.

**Yamada, N., Tanihara, K., Takada, A., Yoriyuzi, T., Tsutsumi, M., Shimomura, H., Tsuji, T. & Date, T. (1996).** Genetic organization and diversity of the 3′ noncoding region of the hepatitis C virus genome. *Virology* **223**, 255–261.

**Yuan, M., Lu, T., Li, C. & Lu, L. (2013).** The evolutionary rates of HCV estimated with subtype 1a and 1b sequences over the ORF length and in different genomic regions. *PLoS ONE* **8**, e64698.

**Zoulim, F., Chevallier, M., Maynard, M. & Trepo, C. (2003).** Clinical consequences of hepatitis C virus infection. *Rev Med Virol* **13**, 57–68.